Octanine F 100 IU/ml prašak i otapalo za otopinu za injekciju Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

octanine f 100 iu/ml prašak i otapalo za otopinu za injekciju

jana pharm d.o.o., lopašićeva 6, zagreb, hrvatska - koagulacijski faktor ix, ljudski - prašak i otapalo za otopinu za injekciju - 100 iu/ml - urbroj: lijek sadrži oko 100 iu/ml ljudskog koagulacijskog faktora ix

OCTANINE F 1000 i.j./10 mL prašak i rastvarač za rastvor za injekciju Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

octanine f 1000 i.j./10 ml prašak i rastvarač za rastvor za injekciju

remedia d.o.o. sarajevo - faktor koagulacije ІХ - prašak i rastvarač za rastvor za injekciju - 1000 i.j./10 ml - 10 ml pripremljenog rastvora za injekciju sadrži: 1000 i.j. faktora koagulacije ix, humanog (100 i.j./ml)

OCTANINE F 500 i.j./5 mL prašak i rastvarač za rastvor za injekciju Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

octanine f 500 i.j./5 ml prašak i rastvarač za rastvor za injekciju

remedia d.o.o. sarajevo - faktor koagulacije ІХ - prašak i rastvarač za rastvor za injekciju - 500 i.j./5 ml - 5 ml pripremljenog rastvora za injekciju sadrži: 500 i.j. faktora koagulacije ix, humanog (100 i.j./ml)

FARMATAN PLUS Hrvatska - hrvatski - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

farmatan plus

phoenix farmacija d.d., zagreb, hrvatska - taninski ekstrakt drva pitomog kestena - prašak za primjenu u hrani i vodi za piće - goveda, svinja, peradi i kunića

Dimenium 50 mikrograma + 100 mikrograma u jednoj dozi, prašak inhalata, dozirani Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

dimenium 50 mikrograma + 100 mikrograma u jednoj dozi, prašak inhalata, dozirani

elpen pharmaceutical co.inc. (sa), 95, marathonos ave., pikermi, attica, grčka - salmeterolksinafoat flutikazonpropionat - prašak inhalata, dozirani - 50 mikrograma + 100 mikrograma - urbroj: jedna doza praška inhalata sadrži 50 mikrograma salmeterola u obliku salmeterolksinafoata i 100 mikrograma flutikazonpropionata

Dimenium 50 mikrograma + 250 mikrograma u jednoj dozi, prašak inhalata, dozirani Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

dimenium 50 mikrograma + 250 mikrograma u jednoj dozi, prašak inhalata, dozirani

elpen pharmaceutical co.inc. (sa), 95, marathonos ave., pikermi, attica, grčka - salmeterolksinafoat flutikazonpropionat - prašak inhalata, dozirani - 50 mikrograma + 250 mikrograma - urbroj: jedna doza praška inhalata sadrži 50 mikrograma salmeterola u obliku salmeterolksinafoata i 250 mikrograma flutikazonpropionata

Dimenium 50 mikrograma + 500 mikrograma u jednoj dozi, prašak inhalata, dozirani Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

dimenium 50 mikrograma + 500 mikrograma u jednoj dozi, prašak inhalata, dozirani

elpen pharmaceutical co.inc. (sa), 95, marathonos ave., pikermi, attica, grčka - salmeterolksinafoat flutikazonpropionat - prašak inhalata, dozirani - 50 mikrograma + 500 mikrograma - urbroj: jedna doza praška inhalata sadrži 50 mikrograma salmeterola u obliku salmeterolksinafoata i 500 mikrograma flutikazonpropionata

Alymsys Europska Unija - hrvatski - EMA (European Medicines Agency)

alymsys

mabxience research sl - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastična sredstva - alymsys in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. alymsys in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. alymsys in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with alymsys in combination with capecitabine. alymsys, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. alymsys, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations. alymsys in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. alymsys, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer. alymsys, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

Inorgan Hrvatska - hrvatski - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

inorgan

siki-vet d.o.o., zagreb, hrvatska - sulfaguanidin, aluminijev salicilat, tanin i kaolin (e 559) - prašak za peroralnu primjenu - goveda, pasa i mačaka

SERZYL 25 µg/1 doza+ 125 µg/1 doza suspenzija za inhalaciju pod pritiskom Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

serzyl 25 µg/1 doza+ 125 µg/1 doza suspenzija za inhalaciju pod pritiskom

viatris bh d.o.o. - flutikazon, Салметерол - suspenzija za inhalaciju pod pritiskom - 25 µg/1 doza+ 125 µg/1 doza - 1 doza suspenzije za inhalaciju pod pritiskom sadrži: 25 mcg salmeterola (u obliku salmeterol ksinafoata) 125 mcg flutikazona (u obliku flutikazon propionata)